Abstract | OBJECTIVE: METHODS: beta- core fragment was measured in urine using the Triton UGP kit. hCG was also measured using the Bayer Immuno-1hCG assay (at Memorial Sloan-Kettering Cancer Center). RESULTS: Over 2 years the patient underwent two courses of chemotherapy and two debulking operations. During this time, hCG levels decreased from 227 to 4.1 mIU/ml. hCG levels were close to the limit of detection (<3 mIU/ml), indicating complete or near-complete regression of disease. At this point urine beta- core fragment levels were determined. High levels were detected 7.9 fmol/ml, consistent with the continued existence of tumor (>1.9 fmol/ml). High-dose chemotherapy (CEM) was started with stem cell harvesting. In the following weeks hCG levels failed to identify the tumor (4.1 to <3 mIU/ml). In the first week (during therapy) beta- core fragment levels increased (12 fmol/ml), and in the following weeks (after therapy) levels regressed to 1.2 fmol/ml. CONCLUSION: Urine beta- core fragment may be a useful tumor maker when serum hCG levels are near to or below the limit of detection.
|
Authors | K Rinne, S Shahabi, L Cole |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 74
Issue 2
Pg. 302-3
(Aug 1999)
ISSN: 0090-8258 [Print] United States |
PMID | 10419751
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright 1999 Academic Press. |
Chemical References |
- Biomarkers, Tumor
- Chorionic Gonadotropin
- Chorionic Gonadotropin, beta Subunit, Human
- Peptide Fragments
- urinary gonadotropin fragment
|
Topics |
- Biomarkers, Tumor
(urine)
- Chorionic Gonadotropin
(urine)
- Chorionic Gonadotropin, beta Subunit, Human
(urine)
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(secondary, urine)
- Peptide Fragments
(urine)
- Trophoblastic Tumor, Placental Site
(secondary, urine)
- Uterine Neoplasms
(urine)
|